Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Vyas, Lila

doi:10.6026/97320630018103

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regular use of MI-DCI tablets had a positive effect on the LH/FSH ratio and the levels of free testosterone and DHEA in the blood, contributed to the restoration of menstruation and spontaneous ovulation. MYO has been shown to improve acne by reducing hyperandrogenism in PCOS patients over 8 weeks along with improving hirsutism [4].…”

Section: Treatment Of Irregular Menstrual Cycle and Hyperandrogenismmentioning

confidence: 99%

Modern Aspects of Treatment of Women With Polycystic Ovary Syndrome

Semenyna

2023

Grundlagen Der Modernen Wissenschaftlichen Forschung

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is one of the most common neuroendocrine syndromes of reproductive age, affecting up to 20% of women in this age group. This condition is characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovary morphology. In the pathophysiology of PCOS, there is a violation of the circadian rhythm of GnRH secretion, which increases the release of LH and decreases FSH. The latter is necessary for the synthesis of aromatases, which convert androgens into estrogens [7]. Another pathophysiological link in the development of PCOS is insulin resistance. Androgen hypersecretion increases the level of insulin resistance, and the hyperinsulinemia that develops due to insulin resistance further increases androgen secretion and induces the production of sex hormone-binding globulin (SHBG) in the liver, thereby increasing the concentration of free testosterone in the blood and even more aggravates disorders associated with hyperandrogenism. In 2003, a consensus of experts at a joint ESHRE/ASRM symposium in Rotterdam adopted diagnostic criteria (remaining relevant to this day), which include a triad of signs: oligoovulation or anovulation; hyperandrogenism (clinical and/or biochemical manifestations); polycystic ovaries detected during ultrasound; diagnosed on the basis of at least two of the following signs [7]. Patients may have different manifestations of this triad depending on the disease phenotype, patient age, and lifestyle. Therefore, treatment strategies are symptomatic and depend on desired goals and clinical preferences.

show abstract

Section: Treatment Of Irregular Menstrual Cycle and Hyperandrogenismmentioning

confidence: 99%

Modern Aspects of Treatment of Women With Polycystic Ovary Syndrome

Semenyna

2023

Grundlagen Der Modernen Wissenschaftlichen Forschung

View full text Add to dashboard Cite

show abstract

“…In addition, Myoinositol is known as the one of components of the vitamin B complex. Inositol also affects insulin metabolism and plays an important role as an insulin sensitizer which is the isomer built from the epimerization pathway [15] [16].…”

Section: Introductionmentioning

confidence: 99%

The Effect Myo-Inositol and D-Chiro-Inositol Co-Supplementation in Women with PCOS: A review

Meliana¹,

Wilujeng²,

Qoribb³

2022

IJRP

View full text Add to dashboard Cite

PCOS is an endocrine condition caused mostly by infertility and menstrual abnormalities. The pathophysiology of PCOS is related to the lack of hormone, reproductive and metabolic regulation which were stimulated by a variety of factors, such as insulin resistance. PCOS treatment strategies are always oral contraceptive pill (OCP) combination oral contraceptive pill, which can cause metabolism and cardiovascular side effect and is difficult to comply with consistently. Several studies stated that the combination between Myo-inositol and D-chiro-inositol (MI-DI) as therapeutics alternative to improve PCOS condition in reproductive-age women. This study investigates combination of MI-DI on PCOS in reproductive-age women. A literature review was used to conduct this investigation through PubMed, ScienceDirect, and Google Scholar databases. 1382 publications were identified in the search results, and 6 studies were relevant and matched the requirements for this investigation. MI-DI co-supplementation is effective to ameliorate metabolic and clinical abnormalities of PCOS patients.

show abstract

“…Поэтому, изучение патогенеза СПКЯ у женщин с нормальным ИМТ является важным. Полученные нами результаты сопоставимы с данными литературы, которые показали, что соотношение мио-инозитола и D-хиро-инозитола 40:1 является оптимальной комбинацией для восстановления овуляции у женщин с СПКЯ [2,10,17].…”

unclassified

Results of Anovulation Therapy in Women With Polycystic Ovary Syndrome With Normal Weight and Without Insulin Resistance

AKBERBEYOVA,

MELIKGASIMOVA

2023

jecm

View full text Add to dashboard Cite

In order to study the effectiveness of the treatment of anovulation with myo-inositol and d-chiroinositol (MI:DCI) (40:1) in patients with polycystic ovary syndrome with normal body weight without insulin resistance, 88 patients with infertility were examined. Anthropometric indicators, hirsutism were measured, body mass index (BMI) was calculated, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone in blood serum, glucose and insulin levels were determined, the HOMA-IR index was calculated. The therapy was carried out with myo-inositol (MI) + D-chiro-inositol (DCI). Statistical analysis was performed using software (SPSS) version 23.0. Patients were divided into 2 groups: group I -40 women with normal BMI and HOMA-IR not exceeding 2.7, group II -48 women with elevated and high BMI and HOMA-IR ≥2.7. The average age of patients in group I was 26.8±1.92 years, in group II -27.0±1.56 years. Before treatment, a significant difference between the groups was observed in the BMI value (p=0.006), in the content of total testosterone, which was significantly higher in group II (p=0.053), as well as in the glucose content (p=0.024) and the HOMA-IR index (p =0.048). After 6-7 months after a 12-week course of treatment, both groups I and II showed a slight decrease in BMI. In patients of group I, the amount of LH in the blood decreased on average by 29.9% (p=0.232), in group II -by 27.0% (p=0.361). The level of FSH increased by 38.1% (p=0.052) and by 40.0% (p=0.053) in comparison with the initial level in groups I and II, respectively. The ratio of LH/FSH compared with the initial level decreased in group I by 32.3% (p=0.024), in group II by 36.6% (p=0.052). The level of total testosterone decreased in group Iby 41.8% (p=0.05), in group II -by 51.3% (p=0.011). In group I, the glucose level decreased by 10.5% (p=0.663), insulin -by 7.6% (p=0.480); in group II -by 25.8% (p=0.115) and 20.1% (p=0.042), respectively; index HOMA-IR in group I decreased by 10.0% (p=0.006), in group II -by 21.0% (p=0.394). After therapy, in the total sample, the proportion of patients with grade I hirsutism decreased from 48.9% to 9.1%; none of the women had grade II hirsutism. In women with PCOS with normal body mass index and insulin resistance, MI:DCI therapy has a positive effect on LH, FSH, LH/FSH and total testosterone ratios, and hirsutism.

show abstract

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Cited by 4 publications

References 18 publications

Modern Aspects of Treatment of Women With Polycystic Ovary Syndrome

Modern Aspects of Treatment of Women With Polycystic Ovary Syndrome

The Effect Myo-Inositol and D-Chiro-Inositol Co-Supplementation in Women with PCOS: A review

Results of Anovulation Therapy in Women With Polycystic Ovary Syndrome With Normal Weight and Without Insulin Resistance

Contact Info

Product

Resources

About